KRAS and colorectal cancer: In the case of cetuximab treatment of colorectal cancer, which targets another receptor of the ERBB-family (the epidermal growth factor receptor) the expression of receptor ligands (i.e. amphiregulin and epiregulin), as well KRAS mutation, predict treatment response [16].